Key Points
- Director Stephen Mayo sold 7,239 shares on March 12 at an average price of $17.02 for about $123,208, cutting his stake by 80.4% to 1,765 shares.
- Sarepta posted a major quarterly earnings miss (EPS of ($3.58) vs. ($0.87) expected) with revenue of $442.93M down 32.7% year‑over‑year, and the stock trades around $16.40 (52‑week range $10.41–$103.32).
- Analysts are mixed with a consensus rating of "Hold" and an average target of $32.15, while institutional investors own roughly 86.68% of the company and have recently adjusted positions.
Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Get Free Report) Director Stephen Mayo sold 7,239 shares of the business's stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $17.02, for a total value of $123,207.78. Following the transaction, the director directly owned 1,765 shares in the company, valued at $30,040.30. This trade represents a 80.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Sarepta Therapeutics Price Performance
Shares of Sarepta Therapeutics stock opened at $16.40 on Friday. The business has a 50 day moving average of $19.43 and a 200 day moving average of $19.98. Sarepta Therapeutics, Inc. has a 52 week low of $10.41 and a 52 week high of $103.32. The company has a market cap of $1.72 billion, a PE ratio of -1.94, a P/E/G ratio of 0.25 and a beta of 0.42. The company has a quick ratio of 1.48, a current ratio of 2.32 and a debt-to-equity ratio of 0.73.
Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported ($3.58) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($2.71). Sarepta Therapeutics had a negative net margin of 38.34% and a negative return on equity of 50.74%. The company had revenue of $442.93 million during the quarter, compared to the consensus estimate of $390.95 million. During the same quarter last year, the firm earned $1.90 EPS. The business's revenue was down 32.7% on a year-over-year basis. As a group, equities research analysts forecast that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current year.
Analysts Set New Price Targets
Several analysts have weighed in on the company. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Sarepta Therapeutics in a research report on Monday, December 29th. Wedbush dropped their price target on Sarepta Therapeutics from $34.00 to $29.00 and set an "outperform" rating on the stock in a research report on Monday, March 2nd. Royal Bank Of Canada upped their price target on Sarepta Therapeutics from $16.00 to $18.00 and gave the stock a "sector perform" rating in a research note on Thursday, January 8th. Wells Fargo & Company decreased their price objective on Sarepta Therapeutics from $45.00 to $38.00 and set an "overweight" rating for the company in a report on Friday, February 27th. Finally, Barclays started coverage on Sarepta Therapeutics in a research report on Wednesday, January 28th. They set an "equal weight" rating and a $20.00 price objective for the company. Nine research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and six have assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $32.15.
Read Our Latest Research Report on SRPT
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC boosted its holdings in Sarepta Therapeutics by 214.2% in the first quarter. AQR Capital Management LLC now owns 5,385 shares of the biotechnology company's stock worth $344,000 after acquiring an additional 3,671 shares in the last quarter. Great Lakes Advisors LLC bought a new position in shares of Sarepta Therapeutics during the first quarter valued at $224,000. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Sarepta Therapeutics by 129.4% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 6,052 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 3,414 shares in the last quarter. Profund Advisors LLC raised its position in shares of Sarepta Therapeutics by 47.0% in the 2nd quarter. Profund Advisors LLC now owns 31,789 shares of the biotechnology company's stock worth $544,000 after purchasing an additional 10,161 shares during the last quarter. Finally, PNC Financial Services Group Inc. raised its position in shares of Sarepta Therapeutics by 61.8% in the 2nd quarter. PNC Financial Services Group Inc. now owns 3,779 shares of the biotechnology company's stock worth $65,000 after purchasing an additional 1,444 shares during the last quarter. Institutional investors own 86.68% of the company's stock.
About Sarepta Therapeutics
(
Get Free Report)
Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta's core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company's mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.
Sarepta's commercial products include several exon-skipping therapies approved by the U.S.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
